-
Innovative bispecific antibody YKST02 officially started Phase I clinical trial
On May 21, 2024, Excyte Biopharma Ltd. officially launched the Phase I clinical trial of YKST02, a bispecific antibody drug for treating relapsed/refractory multiple myeloma, in Beijing.Prof. Chen Wen
2024/06/17 admin 640
-
First in human (FIH) dosing completed for YKST02, a bispecific antibody drug for multiple myeloma immunotherapy in Phase I clinical trial
On June 14, 2024, the FIH dosing safely completed in the Phase I clinical trial of YKST02 (anti-CD3×BCMA), a bispecific antibody drug independently developed by Excyte Biopharma Ltd. (Excyte), for the
2024/06/17 admin 224
-
The IND application for YKST02 has been approved, and Phase I clinical trials will start soon
On April 30, 2024, YKST02, an innovative bispecific antibody developed by Excyte Biopharma Ltd, officially received IND approval from the Center for Drug Evaluation of NMPA. YKST02 targets BCMA and CD
2024/05/21 admin 347
-
The signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held
On April 8, 2024, the signing ceremony for the Phase Ib/II clinical study of YK012 in the treatment of ALL was successfully held in Beijing between Excyte Biopharma Ltd. (hereinafter referred to as &q
2024/04/22 admin 343
-
NHL/ALL Immunotherapy Candidate Double Antibody YK012 Phase I Clinical Trial Completed First Subject Administration
NHL/ALL免疫治疗候选双抗药物YK012 I期临床试验完成首例受试者给药 2023年5月24日，益科思特（北京）医药科技发展有限公司开发的用于治疗复发/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012（CD3×CD19）I期临床研究在中国医学科学院肿瘤医院I期病房完成首例给药。当日上午9:40，YK012注射液通过微量注射泵及输注管路缓缓流入受试者体内，至给药后24h，受试者无
2023/06/07 admin 277
-
NHL/ALL immunotherapy candidate dual antibody drug YK012 has officially entered the phase I clinical trial phase
NHL/ALL免疫治疗候选双抗药物YK012 正式进入I期临床试验阶段2023年5月8日，益科思特（北京）医药科技发展有限公司开发的用于治疗复发性/难治性B细胞非霍奇金淋巴瘤的双特异性抗体药物YK012（CD3×CD19）I期临床研究在京正式启动。5月9日，首例受试者顺利签署知情同意书。中国医学科学院肿瘤医院临床研究中心副院长、肿瘤内科主任石远凯教授（左2），益科思特（北京）医药科技发
2023/06/07 admin 223
